Pharmaceutical Industry Reports Telmisartan Market Size, Share, Outlook, and Analy | Page 2

REPORT DESCRIPTION
Telmisartan Market – Overview
Prevalence of high blood pressures, is increasing globally attributed to rising geriatric population, chronic
disorders such as diabetes, and changing lifestyles which in turn is expected to increase the demand for
telmisartan in global market. According to Blood Pressure UK, 2017 update, high blood pressure is the leading
cause of heart disease and stroke, killing around 7.5 million people worldwide every year. In 1975, 594 million
people were suffering from high blood pressure which increased to 1.1 billion in 2015 and is thought to be due to
population growth and an aging population. Thus, rise in geriatric population suffering from high blood pressure
is expected to be major factor for growth of telmisartan market in the forecast period.
Furthermore, increasing approvals for Abbreviated new Drug Application (ANDA) for manufacturing of generic
telmisartan tablets is propelling growth of telmisartan in the global market. For instance, in July 2014, Glenmark
Generics Inc., USA—a subsidiary of Glenmark Generics Limited—received ANDA approval from the U.S. Food
and Drug Administration (USFDA) for telmisartan tablets.
Telmisartan is an angiotensin receptor blocker (ARB) used alone or in combination with other agents for therapy
of hypertension, in cardiac arrest, and in stroke management. Telmisartan was approved for use in the U.S., for
treatment of hypertension in 1998.